Rules Based Medicine (RBM; Austin, TX), a biomarker testing laboratory, announced today the launch of CardiovascularMAP.
Based on RBM’s proprietary Multi-Analyte Profiling (MAP) platform, CardiovascularMAP is designed to advance the development of drugs for cardiovascular disease. Pharmaceutical and biotechnology groups collaborated to design the tool, which combines common biomarkers with additional ones to identify new patterns of disease.
"RBM is providing access to the most comprehensive array of cardiovascular biomarkers ever
assembled in one panel,” said George P. Rodgers, MD, FACC, past chairman of the
American College of Cardiology Board of Governors, in a press release. “Accurate measurement of these
biomarkers clearly has the potential to accelerate CVD research programs."
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.